[1] Moses JW, LeonMB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patientswith stenosis in a native coronary artery[J]. N Engl J Med, 2003, 349(14): 1315-1323.
[2] AbalM, Andreu JM, Barasoain I, et al. Taxanes:microtubule and centrosome targets, and cell cycle dependent mechanisms of action[J]. Curr Cancer Drug Targets, 2003, 3(3): 193-203.
[3] Sherr CJ, Roberts JM.CDK inhibitors: positive and negative regulators of G1 phase progression[J]. Genes Dev, 1999, 13(12): 1501-1512.
[4] Holmes DR, LeonMB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial.A randomized trial of a sirolimus-eluting stent versus a standared stent in patients at high risk for coronary restenosis[J]. Circulation, 2004, 109(5): 634-640.
[5] Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial[J]. JAMA, 2005, 294(10): 1215-1223.
[6] Rahel BM, Laarman GJ, Suttorp MJ, et al. Primary stenting of occluded native coronary arteries II-rationale and design of the PRISON II study: a randomized comparison of baremetal stent implantation with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions[J]. Am Heart J, 2005, 149(3): 1-3.
[7] Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation[J]. J Am Coll Cardiol, 2005, 45(3): 351-356.
[8] Dibra A, KastratiA, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients[J]. N Engl JMed, 2005, 353(7): 663-670.
[9] Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions[J]. Circulation, 2004, 109(10): 1244-1249.
[10] Chieffo A, Stankovic G, Bonizzoni E, et al. Early and midterm results of drug-eluting stent implantation in unprotected left main[J]. Circulation, 2005, 111(6): 791-795.
[11] Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the rapamy cin-eluting stent evaluated at rotterdam cardiology hospital(RESEARCH) study[J]. Circulation, 2004, 109(11): 1366-1370.
[12] Iakovou I, Schmidt T, Ge L, et al. Angiographic patterns of restenosis after paclitaxel-eluting stent implantation[J]. J Am Coll Cardiol, 2005, 45(5): 805-806.
[13] KastratiA, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus-or paclitaxel-eluting stents[J]. Circulation, 2006, 113(19): 2293-2300.
[14] Lee CW, Park DK, Lee BK, et al. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries[J]. Am J Cardiol, 2006, 97(4): 506-511.
[15] Hong MK, Lee CW, Kim YH, et al. Intravascular ultrasound predictors and their cut-off values for angiographic restenosis after sirolimus-eluting stent implantation[J]. JACC, 2006, 47(4): 189A.
[16] Mauri L, O’Malley AJ, Popma JJ, et al. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents[J]. Am J Cardiol, 2005, 95(10): 1140-1145.
[17] Hong SJ, Kim MH, Ahn TH, et al. Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes[J]. Heart, 2006, 92(8): 1119-1124.
[18] Berenguer A, Mainar V, Bordes P, et al. Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high-risk patients[J]. Am Heart J, 2005, 150(3): 536-542.
[19] Takebay ashi H, Kobayashi Y, Mintz GS, et al. Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation[J]. Am J Cardiol, 2005, 95(4): 498-502.
[20] Moussa ID, Moses JW, Kuntz RE, et al. The fate of patients with clinical recurrence after sirolimus-eluting stent implantation(a two-year follow-up analy sis from the SIRIUS trial)[J]. Am J Cardiol, 2006, 97(11): 1582-1584.
[21] Lemos PA, vanMieghem CA, Arampatzis CA, et al. Post sirolimus-eluting stent restenosis treated with repeat percutaneous intervention late angiographic and clinical outcomes[J]. Circulation, 2004, 109(21): 2500-2502.
[22] Ferri N, Granata A, Pirola C, et al. Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1 cyclin E expression[J]. Mol Pharmacol, 2008, 74(1): 144-153.
[23] Sheiban I, Villata G, Bollati M, et al. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent[J]. Vasc Health Risk Manag, 2008, 4(1): 31-38.
[24] 张志民, 高艳霞, 刘怀霖, 等. 温通煎能预防冠心病患者介入治疗后再狭窄[J]. 中国动脉硬化杂志, 2006, 14(7): 610-613.
[25] 孟庆杰, 王阶, 吴荣.冠心病介入术后的中医药干预进展[J]. 中国中药杂志, 2008, 33(8): 962-964. |
